Advertisement

Lexington-based GI Dynamics Inc. recently received approval in Australia by the Therapeutic Goods Administration (TGA) to use its EndoBarrier Gastrointestinal Liner for the treatment of Type 2 Diabetes and obesity.

“Gaining approval to commercialize the EndoBarrier in Australia is another important milestone for our company,” said Stuart A. Randle, chief executive officer of GI Dynamics, in a statement.

SOURCE

Advertisement
Advertisement